RGEN
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Repligen Corporation - Common Stock (RGEN) [ST]
www.repligen.com ↗▲ 2.21%
prev close
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Congressional Trades
3
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
1 buys · 2 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-31 | RGENRepligen Corporation - Common Stock | Sell | $1,001 - $15,000 | 333d ago | — | |
| 2025-10-30 | RGENRepligen Corporation - Common Stock | Sell | $1,001 - $15,000 | 333d ago | — | |
| 2025-07-22 | RGENRepligen Corporation - Common Stock | Buy | $1,001 - $15,000 | 433d ago | — |
2025-10-31
Lisa McClain
RGEN
Amount
$1,001 - $15,000
Filed
333d ago
2025-10-30
Lisa McClain
RGEN
Amount
$1,001 - $15,000
Filed
333d ago
2025-07-22
Lisa McClain
RGEN
Amount
$1,001 - $15,000
Filed
433d ago
Recent News
Powered by Polygon.io
Continuous Bioprocessing Technologies Market - Global Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable Biomanufacturing
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-31 · Sale
$1,001 - $15,000
Lisa McClain
2025-10-30 · Sale
$1,001 - $15,000
Lisa McClain
2025-07-22 · Purchase
$1,001 - $15,000